Acute on Chronic Liver Failure
Acute on Chronic Liver Failure Market

Acute-on-Chronic Liver Failure (ACLF) is a syndrome in cirrhosis that is characterized by acute decompensation (AD), organ failure(s), and high short-term mortality. 


Type-A ACLF is an acute worsening of liver function in a patient with chronic liver disease. Type-B ACLF occurs when this acute decompensation occurs in patients with cirrhosis, while type-C ACLF is an acute worsening of liver functions in decompensated cirrhotics.


Acute-on-Chronic Liver Failure Epidemiological Segmentation 

The Epidemiological Segmentation of Acute-on-Chronic Liver Failure in 7MM from 2017 to 2030 is segmented as:- 

  • Cases of Acute-on-chronic liver failure
  • Cases of Acute-on-Chronic Liver Failure by Grades
  • Organ failures associated with Acute-on-Chronic Liver Failure
  • Potential precipitating events of Acute-on-Chronic Liver Failure


Acute-on-Chronic Liver Failure Epidemiology 

  • The total population of Acute-on-Chronic Liver Failure in 7MM was 60,521 cases in 2017. 
  • Grade-wise of Acute-on-Chronic Liver Failure prevalent cases in 2017
  • Grade 1- 6,089  
  • Grade 2- 4,810 
  • Grade 3 -1,677  
  • The population of ACLF cases in the United States was 12,577 in 2017. 


Acute-on-Chronic Liver Failure Market

The therapeutic market of Acute-on-Chronic Liver Failure (ACLF) in 7MM in 2017 was USD 70.55 million. 


Acute-on-Chronic Liver Failure Market Drivers

  • Absence of curative and disease-specific treatment options
  • Progress in the understanding of disease
  • Innovative therapeutic approaches 


Acute-on-Chronic Liver Failure Market Barriers

  • Lack of epidemiology data
  • Need for standard diagnostic criteria
  • Uncertainty related to cell-based therapies 


Acute-on-Chronic Liver Failure Emerging Drugs 

The Emerging Drugs of the Acute-on-Chronic Liver Failure market are 

  • Albutein (PE-A 5%)
  • HepaStem

And many others. 


Other Promising Acute-on-Chronic Liver Failure Candidates

  • APZ2
  • VS-01
  • Livantra


Acute-on-Chronic Liver Failure Key Players

The key players in the Acute-on-Chronic Liver Failure market are

  • Grifols Therapeutics
  • Promethera Biosciences
  • RHEACELL
  • Versantis
  • Martin Pharmaceuticals 

And many others.